Question 1

Am I eligible for this trial based on my current treatment and cancer type?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) clinical trial (NCT06819007). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) clinical trial (NCT06819007). Contact the study team or your healthcare provider for specific answers.

Question 3

How does the combination of T-DXd and Bevacizumab compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) clinical trial (NCT06819007). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) clinical trial (NCT06819007). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific side effects I should be aware of with T-DXd?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) clinical trial (NCT06819007). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) clinical trial (NCT06819007). Contact the study team or your healthcare provider for specific answers.

What this study is about